Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684381 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
A Phase 4 study, sponsored by Emmaus Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT04684381: Completed Phase 4 study, sponsored by Emmaus Medical.
NCT04684381 is a Phase 4 study that has completed, run by Emmaus Medical. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04684381, a Phase 4 study, has completed, sponsored by Emmaus Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
L-glutamine has been approved in the US to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. The purpose of this single-center, open-label, phase 4 study is to evaluate the pharmacokinetic characteristics and safety of L-glutamine in patients with SCD.
Primary Outcome
PK (AUC)
Interventions
- DRUG L-glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
What the finished NCT04684381 record still lists
NCT04684381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which L-glutamine is the first listed.
NCT04684381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04684381 about?
NCT04684381 is a clinical study titled "Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients". L-glutamine has been approved in the US to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. The purpose of this single-center, open-label, phase 4 study is to evaluate the pharmacokinetic characteristics and safety of L-glutamine i...
What is the current status of trial NCT04684381?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2021-01-04. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04684381?
The interventions under investigation include: L-glutamine (DRUG).
Who is sponsoring clinical trial NCT04684381?
This trial is sponsored by Emmaus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04684381's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI